Lexeo Therapeutics, Inc. LXEO
We take great care to ensure that the data presented and summarized in this overview for Lexeo Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in LXEO
Top Purchases
Top Sells
About LXEO
Insider Transactions at LXEO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2024
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+50.0%
|
-
|
|
Jun 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.43%
|
$85,000
$17.74 P/Share
|
|
Jun 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.77%
|
$10,000
$2.33 P/Share
|
|
May 13
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.85%
|
$65,000
$13.22 P/Share
|
|
May 13
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.77%
|
$10,000
$2.33 P/Share
|
|
Feb 02
2024
|
Eric Adler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,875
+50.0%
|
-
|
|
Jan 05
2024
|
Jenny Robertson Chief Legal and Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,750
+50.0%
|
-
|
|
Jan 05
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+20.4%
|
-
|
|
Nov 07
2023
|
Paul Mc Cormac Chief Technical Officer |
BUY
Conversion of derivative security
|
Direct |
3,191
+15.54%
|
-
|
|
Nov 07
2023
|
Omega Fund Vi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
454,545
+17.4%
|
$4,999,995
$11.0 P/Share
|
|
Nov 07
2023
|
Omega Fund Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,703,078
+32.22%
|
-
|
|
Nov 07
2023
|
Longitude Capital Partners Iv, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
454,545
+15.04%
|
$4,999,995
$11.0 P/Share
|
|
Nov 07
2023
|
Longitude Capital Partners Iv, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,112,555
+31.56%
|
-
|
|
Nov 07
2023
|
Invest A/S Lundbeckfond > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
227,272
+11.02%
|
$2,499,992
$11.0 P/Share
|
|
Nov 07
2023
|
Invest A/S Lundbeckfond > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,608,687
+32.57%
|
-
|
Last 12 Months Summary
Buy / Acquisition
6.7M
Shares
From
12
Insiders
| Conversion of derivative security | 5.43M shares |
|---|---|
| Open market or private purchase | 1.14M shares |
| Grant, award, or other acquisition | 126K shares |
| Exercise of conversion of derivative security | 10K shares |
Sell / Disposition
10K
Shares
From
1
Insiders
| Open market or private sale | 10K shares |
|---|